Síguenos en Twitter       Síguenos en Facebook       Síguenos en YouTube       Siguenos en Linkedin       Correo Grupsagessa       Gmail       Yahoo Mail       Dropbox       Instagram       Pinterest       Slack       Google Drive       Print       StumbleUpon

SOBRE EL AUTOR **

Mi foto
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com

WORLD EMERGENCY MEDICINE SOCIETIES & RELATED

EMERGENCY MEDICINE DAY: May 27

Buscar en contenido

Contenido:

sábado, 24 de octubre de 2015

Andexanet alfa: FXa Inhibitor Antidote

"Potential first-in-class recombinant, modified Factor Xa molecule that is being developed as an antidote for patients receiving a Factor Xa inhibitor who suffer a major bleeding episode or who may require emergency surgery...
Currently being evaluated in two randomized, double-blind, placebo-controlled ANNEXA™ (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors) Phase 3 studies that are studying the safety and efficacy of andexanet alfa in reversing anticoagulation induced by Eliquis® (apixaban) or XARELTO® (rivaroxaban) rapidly after an IV bolus and sustaining that effect through a continuous infusion."
https://www.portola.com/clinical-development/andexanet-alfa-prt4445-fxa-inhibitor-antidote/